DK1567146T3 - Iontophoretisk levering af rotigotin til behandlingen af Parkinsons sygdom - Google Patents

Iontophoretisk levering af rotigotin til behandlingen af Parkinsons sygdom

Info

Publication number
DK1567146T3
DK1567146T3 DK03785652T DK03785652T DK1567146T3 DK 1567146 T3 DK1567146 T3 DK 1567146T3 DK 03785652 T DK03785652 T DK 03785652T DK 03785652 T DK03785652 T DK 03785652T DK 1567146 T3 DK1567146 T3 DK 1567146T3
Authority
DK
Denmark
Prior art keywords
rotigotine
parkinson
disease
treatment
iontophoretic delivery
Prior art date
Application number
DK03785652T
Other languages
English (en)
Inventor
Hans-Michael Wolff
Johanna Aaltje Bouwstra
Gai Ling Li
Akhmad Kharis Nugroho
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32309357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1567146(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of DK1567146T3 publication Critical patent/DK1567146T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
DK03785652T 2002-12-02 2003-11-21 Iontophoretisk levering af rotigotin til behandlingen af Parkinsons sygdom DK1567146T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026871A EP1426049B1 (en) 2002-12-02 2002-12-02 Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
PCT/EP2003/013111 WO2004050083A1 (en) 2002-12-02 2003-11-21 Iontophoretic delivery of rotigotine for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
DK1567146T3 true DK1567146T3 (da) 2007-02-19

Family

ID=32309357

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02026871T DK1426049T3 (da) 2002-12-02 2002-12-02 Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
DK03785652T DK1567146T3 (da) 2002-12-02 2003-11-21 Iontophoretisk levering af rotigotin til behandlingen af Parkinsons sygdom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02026871T DK1426049T3 (da) 2002-12-02 2002-12-02 Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom

Country Status (24)

Country Link
US (1) US7632859B2 (da)
EP (2) EP1426049B1 (da)
JP (1) JP2006514937A (da)
KR (1) KR101168431B1 (da)
CN (1) CN100333723C (da)
AT (2) ATE295726T1 (da)
AU (1) AU2003294718B2 (da)
BR (1) BR0316947A (da)
CA (1) CA2505040C (da)
CY (1) CY1106256T1 (da)
DE (2) DE60204229T2 (da)
DK (2) DK1426049T3 (da)
ES (2) ES2239196T3 (da)
HK (2) HK1065706A1 (da)
IL (1) IL168387A (da)
MX (1) MXPA05005462A (da)
NO (1) NO335491B1 (da)
NZ (1) NZ540190A (da)
PL (1) PL219696B1 (da)
PT (2) PT1426049E (da)
RU (2) RU2339372C2 (da)
SI (2) SI1426049T1 (da)
WO (1) WO2004050083A1 (da)
ZA (1) ZA200503750B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
ME02275B (me) * 2007-11-28 2016-02-20 Ucb Pharma Gmbh Polimorfni oblik rotigotina
DE102008010223A1 (de) 2008-02-20 2009-08-27 Wash Tec Holding Gmbh Reinigungsvorrichtung
DE202008002377U1 (de) 2008-02-20 2009-06-25 Washtec Holding Gmbh Reinigungsvorrichtung
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
DK2515887T3 (da) 2009-12-22 2018-09-17 Ucb Biopharma Sprl Polyvinylpyrrolidon til stabilisering af en faststofdispersion af den ikke-krystallinske form af rotigotin
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
US11633367B2 (en) 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
WO2015177209A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
CA2948221C (en) 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
CN109415335B (zh) * 2016-07-21 2020-06-05 山东绿叶制药有限公司 罗替戈汀山嵛酸酯及其制备方法和用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108991A (en) * 1975-06-19 1992-04-28 Whitby Research, Inc. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4996226A (en) * 1984-08-13 1991-02-26 Whitby Research, Inc. Method and compositions for treatment of parkinsonism syndrome in mammels
EP0257086B1 (en) * 1986-01-31 1993-01-20 WHITBY RESEARCH, Inc. Skinpenetration enhancing compositions
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5142044A (en) * 1986-04-23 1992-08-25 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4801586A (en) * 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5073544A (en) * 1986-08-15 1991-12-17 Whitby, Inc. Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes
US4917896A (en) * 1986-08-15 1990-04-17 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5118845A (en) * 1986-09-29 1992-06-02 Whitby Research, Inc. Penetration enhancer for transdermal delivery of systemic agents
US4808414A (en) * 1986-09-29 1989-02-28 Nelson Research & Development Co. Amide penetration enhancers for transdermal delivery of systemic agents
US5273757A (en) * 1987-09-01 1993-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Apparatus for the delivery of substances, processes for the production thereof and use thereof
US5071645A (en) * 1987-10-19 1991-12-10 Ppg Industries, Inc. Process of producing an active agent delivery device
ES2032570T3 (es) * 1987-11-20 1993-02-16 Farmitalia Carlo Erba S.R.L. Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe).
US4915950A (en) * 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5472946A (en) 1988-04-08 1995-12-05 Peck; James V. Transdermal penetration enhancers
DE3827561C1 (da) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5234945A (en) * 1989-05-09 1993-08-10 Whitby Research, Inc. Method of producing body weight and food intake using a dopamine D2 receptor agonist
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5271940A (en) * 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
AU658134B2 (en) * 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5147916A (en) * 1990-02-21 1992-09-15 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive composition and related methods and articles
US5246997A (en) * 1990-02-21 1993-09-21 Dow Corning Corporation Method of making a hot-melt silicone pressure sensitive adhesive-coated substrate
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US6086905A (en) * 1991-03-21 2000-07-11 Peck; James V. Topical compositions useful as skin penetration barriers
US5273756A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5234690A (en) * 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5273755A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
WO1993003697A1 (en) * 1991-08-27 1993-03-04 Cygnus Therapeutic Systems Transdermal formulations for administering prazosin
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE4301781C2 (de) * 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
WO1995001767A1 (en) * 1993-07-08 1995-01-19 Cygnus Therapeutic Systems Monolithic matrix transdermal delivery system
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
ATE211655T1 (de) * 1993-09-22 2002-01-15 Hisamitsu Pharmaceutical Co Iontophoresematrix
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US5670501A (en) * 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US6316022B1 (en) * 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
JP3534775B2 (ja) * 1995-06-07 2004-06-07 オーソ―マクニール ファーマシューティカル，インコーポレイテッド １７−デアセチルノルゲスチマートを単独でまたはエストロゲンと組み合わせて投与するための経皮パッチおよび方法
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US6063398A (en) * 1995-09-20 2000-05-16 L'oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6221627B1 (en) * 1997-02-24 2001-04-24 Smithkline Beecham Corporation cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor
US5879701A (en) * 1997-02-28 1999-03-09 Cygnus, Inc. Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
US6242572B1 (en) * 1997-05-13 2001-06-05 Smithkline Beecham Corporation Human G protein coupled lysophosphatidic acid receptor
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
JP3507437B2 (ja) * 1998-05-13 2004-03-15 シグナス， インコーポレイテッド 経皮サンプリング系のための収集アセンブリ
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
DE69913153D1 (de) * 1998-09-17 2004-01-08 Cygnus Therapeutic Systems Gerät zum zusammendrücken einer gel/sensor-einheit
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
AU5325000A (en) * 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
NZ519069A (en) * 1999-11-29 2004-06-25 Lohmann Therapie Syst Lts Transdermal therapeutic systems having improved stability and their production
US20020110585A1 (en) * 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
KR20050045946A (ko) * 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
JP4288263B2 (ja) * 2002-10-25 2009-07-01 コレジウム ファーマシューティカル， インク． ｐ−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
WO2005070428A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss

Also Published As

Publication number Publication date
AU2003294718B2 (en) 2008-07-31
EP1426049A1 (en) 2004-06-09
IL168387A (en) 2009-05-04
CN100333723C (zh) 2007-08-29
JP2006514937A (ja) 2006-05-18
NZ540190A (en) 2007-03-30
US7632859B2 (en) 2009-12-15
EP1567146B1 (en) 2006-10-18
MXPA05005462A (es) 2005-07-25
PT1567146E (pt) 2007-01-31
DE60309203D1 (de) 2006-11-30
ES2239196T3 (es) 2005-09-16
DK1426049T3 (da) 2005-08-22
WO2004050083A1 (en) 2004-06-17
CY1106256T1 (el) 2011-06-08
ATE342719T1 (de) 2006-11-15
US20040116537A1 (en) 2004-06-17
RU2005114749A (ru) 2006-01-20
SI1567146T1 (sl) 2007-02-28
DE60309203T2 (de) 2007-08-23
DE60204229T2 (de) 2006-02-02
RU2478383C2 (ru) 2013-04-10
PL377575A1 (pl) 2006-02-06
RU2339372C2 (ru) 2008-11-27
NO335491B1 (no) 2014-12-22
EP1426049B1 (en) 2005-05-18
ZA200503750B (en) 2006-11-29
ES2273062T3 (es) 2007-05-01
SI1426049T1 (en) 2005-08-31
BR0316947A (pt) 2005-10-18
HK1079108A1 (en) 2006-03-31
PL219696B1 (pl) 2015-06-30
HK1065706A1 (en) 2005-03-04
NO20052959L (no) 2005-06-16
EP1567146A1 (en) 2005-08-31
CA2505040A1 (en) 2004-06-17
RU2008121750A (ru) 2009-12-20
DE60204229D1 (de) 2005-06-23
KR101168431B1 (ko) 2012-07-25
CN1720041A (zh) 2006-01-11
KR20050086886A (ko) 2005-08-30
ATE295726T1 (de) 2005-06-15
AU2003294718A1 (en) 2004-06-23
PT1426049E (pt) 2005-09-30
CA2505040C (en) 2012-10-16

Similar Documents

Publication Publication Date Title
DK1567146T3 (da) Iontophoretisk levering af rotigotin til behandlingen af Parkinsons sygdom
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
CY1114645T1 (el) Συνθεση αλατος φεντανυλης για ρινικη χορηγηση
DK1687049T3 (da) Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer
EA200601777A1 (ru) Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии
BRPI0413785A (pt) composto, composição, e, método de tratamento de distúrbio hiperproliferativo
DK1706128T3 (da) Farmaceutiske sammensætninger og fremgangsmåder til insulin-behandling
BR0308813A (pt) Tratamento de tuberculose usando derivados de pleuromutilina
ATE359079T1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape
DE602004013431D1 (de) Identifikation von therapeutische verbindungen.
ATE504302T1 (de) Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten
BR0308753A (pt) Método para produzir pseudo-ilhotas
RU2003135781A (ru) Способ лечения ревматоидного артрита
WO2004083398A3 (en) Therapeutic uses of hmgn1 and hmgn2
ATE382367T1 (de) Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern
RU2004113429A (ru) Способ лечения зрительного утомления у пользователей компьютерами
DE602004013695D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Hyperhomocysteinämie
BR0211522A (pt) Tratamento de dor crÈnica com 3-arilóxi-3-fenilpropanaminas
ITPG20020109A1 (it) Vaschetta ionoforesi per il trattamento dell'iperidrosi palmare e plantare.
UA2858U (uk) Спосіб лікування наркоманії
ITGE20040064A1 (it) Metodo per l'applicazione di campo elettromagnetico per il trattamento di esseri umani,animali o piante.
UA4215U (uk) Спосіб лікування тунельних нейропатій нижніх кінцівок
RU2003103882A (ru) Средство для коррекции компонентов системы комплемента крови при лечении хронического пиелонефрита
UA2986U (uk) Спосіб лікування розсіяного склерозу